"TUCC provides innovative, evidence-based, and compassionate urologic care. Our singular focus is on giving you the best experience. We deliver excellence every day because we specialize in U! TUCC physicians operate under a unique philosophy in healthcare - they’re subspecialists and will ensure you’re paired with a doctor experienced in the treatment you need. And they listen. Visit our state-of-the-art Denver facility, and experience the TUCC difference for yourself."

During the past decade, The Urology Center of Colorado conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 34 clinical trials were completed, i.e. on average, 91.9% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 15 clinical trials were completed. i.e. 83.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Urology Center of Colorado" #1 sponsor was "Janssen Research & Development, LLC" with 11 trials, followed by "Dendreon" with 8 trials sponsored, "Ferring Pharmaceuticals" with 5 trials sponsored, "Pfizer" with 4 trials sponsored and "Spectrum Pharmaceuticals, Inc" with 4 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Urology Center of Colorado" #1 collaborator was "National Cancer Institute (NCI)" with 4 trials as a collaborator, "Astellas Pharma Inc" with 3 trials as a collaborator, "NRG Oncology" with 3 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 2 trials as a collaborator and "Allergan" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "The Urology Center of Colorado" are "Prostate Cancer" (21 trials), "Bladder Cancer" (8 trials), "Urinary Bladder Neoplasms" (5 trials), "Prostatic Neoplasms" (4 trials) and "Carcinoma in Situ" (3 trials). Many other conditions were trialed in "The Urology Center of Colorado" in a lesser frequency.

Most popular intervention types in "The Urology Center of Colorado" are "Drug" (48 trials), "Biological" (17 trials), "Other" (9 trials), "Device" (4 trials) and "Radiation" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "sipuleucel-T" (5 trials), "Degarelix" (4 trials), "Enzalutamide" (4 trials) and "Apaziquone" (3 trials). Other intervention names were less common.

The vast majority of trials in "The Urology Center of Colorado" are 42 trials for "Male" genders and 26 trials for "All" genders.

Currently, there are NaN active trials in "The Urology Center of Colorado". undefined are not yet recruiting, 11 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in The Urology Center of Colorado, undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in The Urology Center of Colorado, 7 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".